Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Salestools Logo

Salestools

The #1 AI Agent for Sales teams and Go To Market teams. Sell more, faster, with less effort.

Product

  • AI Sales Agents
  • Intent Data
  • Technology Data
  • Visitor Tracking
  • Co-Pilot
  • Social Selling

Solutions

  • Customer Service
  • E-commerce
  • SaaS
  • Enterprise
  • Small Business

Resources

  • The Report
  • Documentation
  • API Reference
  • Help Center
  • Blog
  • Case Studies
  • Webinars

Company

  • About
  • Careers
  • Press
  • Contact
  • Partners

Our locations

  • New York, HQ
  • Bucharest, AI Research Lab
  • Zug, Switzerland

Β© 2026 Salestools. All rights reserved.

Data Terms & SecurityPrivacy PolicyTerms of ServiceAcceptable Use
All systems operational
Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Back to Reports
Fundraising

Talkspace

Talkspace Raises $250M in PIPE

30 West 26th Street, New York, NY 10010June 30, 20242 min read
Employees
800+

Talkspace Raises $250M in PIPE


Talkspace has successfully raised $250M in a PIPE at a $1.4B valuation led by Norwest Venture Partners, Spark Capital, Revolution Growth, Qumra Capital, Hudson Bay Capital.


Company Overview


Talkspace is a HealthTech company headquartered in 30 West 26th Street, New York, NY 10010, founded in 2012 with 800+ employees.


Online therapy platform


Fundraising Details


  • Amount Raised: $250M
  • Round Type: PIPE
  • Valuation: $1.4B
  • Date: 2024-06-30
  • Investors: Norwest Venture Partners, Spark Capital, Revolution Growth, Qumra Capital, Hudson Bay Capital

About Talkspace


Online therapy platform The company is positioned in the HealthTech sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: 30 West 26th Street, New York, NY 10010
  • Founded: 2012
  • Team Size: 800+
  • Industry: HealthTech

What This Means


This funding round demonstrates strong investor confidence in Talkspace's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The HealthTech sector continues to attract significant investment as companies innovate to meet evolving market demands. Talkspace's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $1.4B valuation marks an important milestone for Talkspace, positioning the company among notable players in the HealthTech industry.


Looking Ahead


With this new capital, Talkspace is well-positioned to execute on its growth strategy and continue building innovative solutions in the HealthTech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-06-30. For more information about Talkspace, visit their headquarters at 30 West 26th Street, New York, NY 10010.

Company Info

Headquarters
30 West 26th Street, New York, NY 10010
Founded
2012
Team Size
800+

Topics

Fundraising(2912)HealthTech(503)PIPETalkspace

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min readβ€’$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min readβ€’$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min readβ€’$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free